Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

Watchdoq May 30, 2025
(MedPage Today) -- New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive...

Read Full Article